Palmoplantar PsoriasisPhase 4NCT06042920

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

A Phase 4 study testing Deucravacitinib in people with Palmoplantar Psoriasis and Genital Psoriasis, run by Bristol-Myers Squibb at 31 sites in 3 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record

Search all trials

Trial summary

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Palmoplantar Psoriasis, Genital Psoriasis
What is being tested?: Deucravacitinib
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 130 participants
Where: 31 sitesin 3 countries
Study dates: 9 Oct 2023to 25 Apr 2025
Phase: Phase 4
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Men and women diagnosed with stable plaque psoriasis with involvement of the palm(s)and/or sole(s) for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1.
Moderate-to-severe non-pustular PP psoriasis, defined as pp-PGA score of ≥ 3 on a 5-pointscale and pp-PASI ≥ 8 at both screening visit and Day 1.
A total maximum of 5 sterile pustules across both palms and soles limited only to psoriatic plaques will be allowed.
Evidence of typical plaque psoriasis outside palms and soles at both screening visit and Day 1.
Deemed by the investigator to be a candidate for phototherapy or systemic therapy.

Show all 13Show fewer

Failed to respond to, or intolerant of ≥ 1 topical therapy.
Men and women diagnosed with stable plaque psoriasis with involvement of the genital area for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1.
Moderate-to-severe GenPs, defined as static Physician's Global Assessment of Genitalia (s-PGA-G) score of ≥ 3 on a 6-point scale at both screening visit and Day 1.
Evidence of typical plaque psoriasis in a non-genital area at both screening visit and Day 1.
Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
Failed to respond to, or intolerant of ≥ 1 topical therapy.

Who cannot join

Target Disease Exceptions
Has non-plaque psoriasis (for PP pustulosis, PP pustular psoriasis, isolated pustules on palms or soles with or without erythema outside psoriatic plaques, guttate, pustular, erythrodermic, and drug-induced psoriasis) at screening or Day 1.
Other protocol-defined inclusion/exclusion criteria apply.

Trial locations and contacts

31 sites in 3 countries.

Country

City, postcode or hospital

31 sites in 3 countries

United States20 sites

Local Institution - 0066
Boardman, Ohio, 44512
Local Institution - 0012
Detroit, Michigan, 48202-3141
Local Institution - 0005
East Windsor, New Jersey, 08520-2505
Local Institution - 0015
Fountain Valley, California, 92708
Local Institution - 0010
Houston, Texas, 77004
Local Institution - 0052
Indianapolis, Indiana, 46250
Local Institution - 0009
Los Angeles, California, 90045-3606
Local Institution - 0055
Mayfield Heights, Ohio, 44124-4005
Local Institution - 0033
Mill Creek, Washington, 98012-1797
Local Institution - 0002
New York, New York, 10003
Local Institution - 0008
New York, New York, 10075
Local Institution - 0062
New York, New York, 10128
Local Institution - 0007
Norfolk, Virginia, 23502-3933
Local Institution - 0050
Phoenix, Arizona, 85006-2722
Local Institution - 0056
Pittsburgh, Pennsylvania, 15213-3403
Local Institution - 0053
Plainfield, Indiana, 46168-2792
Local Institution - 0029
Rockville, Maryland, 20850-6243
Local Institution - 0004
Santa Monica, California, 90404
Local Institution - 0057
Skokie, Illinois, 60077-1049
Local Institution - 0001
Winston-Salem, North Carolina, 27157

Other trials in United States

Canada7 sites

Local Institution - 0065
Montreal, Quebec, H1Y 3L1
Local Institution - 0054
Montreal, Quebec, H2X 2V1
Local Institution - 0058
Newmarket, Ontario, L3Y 5G8
Local Institution - 0059
Québec, Quebec, G1W 4R4
Local Institution - 0061
Saint-Jérôme, Quebec, J7Z 7E2
Local Institution - 0064
Saskatoon, Saskatchewan, S7K 2C1
Local Institution - 0060
Toronto, Ontario, M3B 0A7

Other trials in Canada

Argentina4 sites

Local Institution - 0034
Ciudad Autonoma Buenos Aires, C, C1425DKG
Local Institution - 0043
Ciudad Autónoma Buenos Aires, B, 1425
Local Institution - 0037
Ciudad Autónoma Buenos Aires, B, C1428DZF
Local Institution - 0042
Rosario, S, 2000

Other trials in Argentina

About this study

Official title: A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Non-Pustular PalmoPlantar and Genital Psoriasis (Psoriatyk Special Sites)

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.

Conditions: Palmoplantar Psoriasis, Genital Psoriasis
Being tested: Deucravacitinib, Placebo
Keywords: Deucravacitinib, BMS-986165, SOTYKTU, Plaque psoriasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

DeucravacitinibDrug
Also called BMS-986165, SOTYKTU
Specified dose on specified days
PlaceboDrug
Specified dose on specified days

Study groups in NCT06042920
Study group	Role	What they receive
Deucravacitinib	Experimental	Not described Receives: Drug: Deucravacitinib
Placebo followed by Deucravacitinib	Placebo comparator	Not described Receives: Drug: Deucravacitinib; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response
PASI-75 is defined as the percentage of participants who achieve at least a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI) total score. PASI assesses erythema, thickness, and scaling of psoriatic lesions (each rated 0-4), weighted by body region involvement (head, arms, trunk, legs), producing a total score from 0-72, where higher scores indicate more severe disease. Baseline is the Week 0 assessment. PASI-75 responder defined as a 75% improvement from baseline in the PASI score.
Measured: Week 16
Percentage of Participants Achieving Static Physician's Global Assessment of Genitalia (sPGA-G) Response
The Static Physician's Global Assessment (sPGA) OF Genitalia is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The sPGA-G 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.
Measured: Week 16

Secondary outcomes (5)

Percentage of Participants Who Achieve a Palmoplantar Physician Global Assessment (Pp-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16
The Palmoplantar Physician's Global Assessment (pp-PGA) is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The pp-PGA 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.
Measured: Week 16
Change From Baseline in Genital Psoriasis Itch (GenPs) Numeric Rating Scale (NRS) Score at Week 16
The Genital Psoriasis Symptoms Scale (GPSS) is a participant-administered questionnaire that contains 8 items regarding GenPs symptoms and has a recall period of 24 hours. The items separately address itch, pain, discomfort, stinging, burning, redness, scaling, and cracking on an 11-point scale where 0 represents "no symptom" and 10 represents "worst symptom imaginable". A total score ranging from 0 (no GenPs symptoms) to 80 (worst imaginable GenPs symptoms)
Measured: Week 16
Number of Participants With Adverse Events
Adverse Events (AEs) are any new or worsening medical occurrences in participants receiving study treatment, regardless of whether they are related to the treatment. AEs include any unfavorable and unintended sign, symptom, or disease temporally associated with treatment. Serious Adverse Events (SAEs) are defined as events that result in death, are life-threatening, require or prolong hospitalization, cause persistent or significant disability, are congenital anomalies/birth defects, or are otherwise medically significant.
Measured: Week 0 through Week 16
Number of Participants With Worst Toxicity Grade 3 or Grade 4 Laboratory Test Results
Blood samples were collected to assess the laboratory parameters. Laboratory toxicities are graded using NCI CTCAE v3.0. Grade 3 and 4 represent severe and life-threatening abnormalities, respectively.
Measured: Week 0 through Week 16
Number of Participants With Vital Sign Summaries Per Categories
Vital signs assessment included heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Heart rate was measured in beats/min and DBP and SBP was measured in mmHG.
Measured: Week 0 through Week 16

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

9 Oct 202325 Apr 2025

First posted21 Sep 2023
Study start9 Oct 2023
Primary completion25 Apr 2025
Study completion25 Apr 2025

Why it stopped: Business objectives have changed

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Palmoplantar PsoriasisStudies of the same condition, open and under way.
More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 4
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 130 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06042920
Sponsor's protocol ID: IM011-1112
Other IDs: 2023-504663-16, U1111-1289-6934, 2023
Status last verified: Mar 2026
First submitted: 12 Sep 2023
Last updated: 17 Apr 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol-Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.htm

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 3
A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
Palmoplantar Psoriasis
RecruitingObservational study
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Acne, Atopic Dermatitis
RecruitingPhase 2
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
Palmoplantar Pustulosis
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Palmoplantar Pustulosis
Not yet recruitingPhase 3
Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis
Palmoplantar Pustulosis (PPP)

All Palmoplantar Psoriasis trials

Study at a glance

From the registry record, last updated by the sponsor on 17 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Non-Pustular PalmoPlantar and Genital Psoriasis (Psoriatyk Special Sites)
ClinicalTrials.gov ID: NCT06042920
Acronym / sponsor ID: IM011-1112
Conditions: Palmoplantar Psoriasis, Genital Psoriasis
Keywords: Deucravacitinib, BMS-986165, SOTYKTU, Plaque psoriasis
Phase: Phase 4
Study type: Interventional
Recruitment status: TerminatedReason stopped: Business objectives have changed
Enrolment: 130 participants (actual)
Lead sponsor: Bristol-Myers SquibbIndustry (pharma, biotech, devices)
Study start: 9 Oct 2023 (actual)
Primary completion: 25 Apr 2025 (actual)
Study completion: 25 Apr 2025 (actual)
First posted: 21 Sep 2023 (actual)
Results: Posted 17 Apr 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 2

Arm	Type	Receives
Deucravacitinib	Experimental	Drug: Deucravacitinib
Placebo followed by Deucravacitinib	Placebo comparator	Drug: Deucravacitinib, Drug: Placebo

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (13 listed)

Men and women diagnosed with stable plaque psoriasis with involvement of the palm(s)and/or sole(s) for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1.
Moderate-to-severe non-pustular PP psoriasis, defined as pp-PGA score of ≥ 3 on a 5-pointscale and pp-PASI ≥ 8 at both screening visit and Day 1.
Evidence of typical plaque psoriasis outside palms and soles at both screening visit and Day 1.
Deemed by the investigator to be a candidate for phototherapy or systemic therapy.

Key exclusion criteria (3 listed)

Target Disease Exceptions
Has non-plaque psoriasis (for PP pustulosis, PP pustular psoriasis, isolated pustules on palms or soles with or without erythema outside psoriatic plaques, guttate, pustular, erythrodermic, and drug-induced psoriasis) at screening or Day 1.
Other protocol-defined inclusion/exclusion criteria apply.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
DeucravacitinibAlso: BMS-986165, SOTYKTUSpecified dose on specified days	Drug	Deucravacitinib, Placebo followed by Deucravacitinib
PlaceboSpecified dose on specified days	Drug	Placebo followed by Deucravacitinib

Primary outcome

Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response
Time frame: Week 16
PASI-75 is defined as the percentage of participants who achieve at least a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI) total score. PASI assesses erythema, thickness, and scaling of psoriatic lesions (each rated 0-4), weighted by body region involvement (head, arms, trunk, legs), producing a total score from 0-72, where higher scores indicate more severe disease. Baseline is the Week 0 assessment. PASI-75 responder defined as a 75% improvement from baseline in the PASI score.
Percentage of Participants Achieving Static Physician's Global Assessment of Genitalia (sPGA-G) Response
Time frame: Week 16
The Static Physician's Global Assessment (sPGA) OF Genitalia is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The sPGA-G 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.

5 secondary outcomes

Percentage of Participants Who Achieve a Palmoplantar Physician Global Assessment (Pp-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16
Time frame: Week 16
Change From Baseline in Genital Psoriasis Itch (GenPs) Numeric Rating Scale (NRS) Score at Week 16
Time frame: Week 16
Number of Participants With Adverse Events
Time frame: Week 0 through Week 16
Number of Participants With Worst Toxicity Grade 3 or Grade 4 Laboratory Test Results
Time frame: Week 0 through Week 16
Number of Participants With Vital Sign Summaries Per Categories
Time frame: Week 0 through Week 16

Results and safety

Results posted to the registry on 17 Apr 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD	30	13
Placebo-Controlled Palmoplantar Psoriasis - Placebo	15	8
Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD	56	29
Placebo-Controlled Genital Psoriasis - Placebo	29	11
Active Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg	0	0
Active Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mg	0	0
Active Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg	0	0
Active Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg	0	0

Primary outcome: Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response

Time frame: Week 16. Number (95% Confidence Interval). Unit: percentage of participants

Measure	Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD n = 16	Placebo Contolled - Palmoplantar Psoriasis - Placebo n = 9
Value	31.3 (11.0 to 58.7)	33.3 (7.5 to 70.1)

Population analysed: Full Analysis Set. Pre-defined to be only assessed for Palmoplantar Psoriasis arms. Only number of participants with data available were included in the analysis.

Primary outcome: Percentage of Participants Achieving Static Physician's Global Assessment of Genitalia (sPGA-G) Response

Time frame: Week 16. Number (95% Confidence Interval). Unit: percentage of participants

Measure	Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD n = 31	Placebo-Controlled Genital Psoriasis - Placebo n = 13
Value	48.4 (30.2 to 66.9)	0 (0 to 24.7)

Population analysed: Full Analysis Set. Pre-defined to be only assessed for Genital Psoriasis arms. Only number of participants with data available were included in the analysis.

5 secondary outcomes are reported in the full results.

Adverse events

Time frame: All-cause mortality, serious and non-serious adverse events were collected from Week 0 through Week 52.. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD	0 of 30 (0%)	9 of 30 (30%)	0 of 30
Placebo-Controlled Palmoplantar Psoriasis - Placebo	0 of 15 (0%)	7 of 15 (46.7%)	0 of 15
Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD	1 of 56 (1.8%)	10 of 56 (17.9%)	0 of 56
Placebo-Controlled Genital Psoriasis - Placebo	0 of 29 (0%)	10 of 29 (34.5%)	0 of 29
Active Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg	1 of 13 (7.7%)	2 of 13 (15.4%)	0 of 13
Active Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mg	2 of 8 (25%)	1 of 8 (12.5%)	0 of 8
Active Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg	4 of 29 (13.8%)	7 of 29 (24.1%)	0 of 29
Active Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg	0 of 10 (0%)	2 of 10 (20%)	0 of 10

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
BMS Clinical Trial InformationLink provided by the sponsor.
BMS Clinical Trial Patient RecruitingLink provided by the sponsor.
Individual participant dataSharing planned: Yes. BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol-Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.htm

Related trials for Palmoplantar Psoriasis

Not yet recruitingPhase 3
A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
Palmoplantar Psoriasis
RecruitingObservational study
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Acne, Atopic Dermatitis
RecruitingPhase 2
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
Palmoplantar Pustulosis
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Palmoplantar Pustulosis
Not yet recruitingPhase 3
Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis
Palmoplantar Pustulosis (PPP)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Bristol-Myers Squibb study director

Bristol-Myers Squibb

31 sites in 3 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Deucravacitinib in people with Palmoplantar Psoriasis and Genital Psoriasis, run by Bristol-Myers Squibb at 31 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 17 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 31 sites in United States, Canada, Argentina. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Apr 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response (time frame: Week 16). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06042920.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2026.